FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011052290> ?p ?o ?g. }

• W2011052290 endingPage "882" @default.
• W2011052290 startingPage "873" @default.
• W2011052290 abstract "We assessed the efficacy, effectiveness and safety of artemether-lumefantrine, which is the most widely used artemisinin-based combination therapy in Africa, against Plasmodium falciparum malaria during an extended follow-up period after initial and repeated treatment.We performed an open-label randomized trial of artemether-lumefantrine with supervised (n=180) and unsupervised intake (n=179) in children <5 years of age with uncomplicated falciparum malaria in rural Tanzania. Recurrent infections between day 14 and day 56 were retreated within the same study arm. Main end points were polymerase chain reaction (PCR)-corrected cure rates by day 56 and day 42 after initial and repeated treatment, respectively, as estimated by survival analysis.The PCR-corrected cure rate after initial treatment was 98.1% (95% confidence interval [CI], 94.2%-99.4%) after supervised and 95.1% (95% CI, 90.7%-98.1%) after unsupervised intake (P=.29). After retreatment of recurrent infections, the cure rates were 92.9% (95% CI, 81.8%-97.3%) and 97.6% (95% CI, 89.3%-98.8%), respectively (P=.58). Reinfections occurred in 46.9% (82 of 175) versus 50.9 % of the patients (relative risk [RR], 0.92 [95% CI, 0.74-1.14]; P=.46) after initial therapy and 32.4% (24 of 74) versus 39.0% (32 of 82) (RR, 0.83 [95% CI, 0.54-1.27]; P=.39) after retreatment. Median blood lumefantrine concentrations in supervised and unsupervised patients on day 7 were 304 versus 194 ng/mL (P<.001) after initial treatment and 253 versus 164 ng/mL (P=.001) after retreatment. Vomiting was the most commonly reported drug-related adverse event (in 1% of patients) after both initial and repeated treatment.Artemether-lumefantrine was highly efficacious even after unsupervised administration, despite significantly lower lumefantrine concentrations, compared with concentration achieved with supervised intake, and was well-tolerated and safe after initial and repeated treatment.ISRCTN69189899." @default.
• W2011052290 created "2016-06-24" @default.
• W2011052290 creator A5000301162 @default.
• W2011052290 creator A5004444553 @default.
• W2011052290 creator A5019096760 @default.
• W2011052290 creator A5024601202 @default.
• W2011052290 creator A5033289218 @default.
• W2011052290 creator A5047802528 @default.
• W2011052290 creator A5060978851 @default.
• W2011052290 creator A5063465178 @default.
• W2011052290 creator A5067883811 @default.
• W2011052290 creator A5084119337 @default.
• W2011052290 creator A5090736522 @default.
• W2011052290 date "2011-03-22" @default.
• W2011052290 modified "2023-09-30" @default.
• W2011052290 title "Efficacy and Effectiveness of Artemether-Lumefantrine after Initial and Repeated Treatment in Children < 5 Years of Age with Acute Uncomplicated Plasmodium falciparum Malaria in Rural Tanzania: A Randomized Trial" @default.
• W2011052290 cites W1594650890 @default.
• W2011052290 cites W1628013173 @default.
• W2011052290 cites W1921967810 @default.
• W2011052290 cites W1990484067 @default.
• W2011052290 cites W1991442399 @default.
• W2011052290 cites W2016954998 @default.
• W2011052290 cites W2039639971 @default.
• W2011052290 cites W2048834380 @default.
• W2011052290 cites W2063467309 @default.
• W2011052290 cites W2090726723 @default.
• W2011052290 cites W2097263871 @default.
• W2011052290 cites W2100109827 @default.
• W2011052290 cites W2106346927 @default.
• W2011052290 cites W2109330385 @default.
• W2011052290 cites W2110269548 @default.
• W2011052290 cites W2112261944 @default.
• W2011052290 cites W2112398378 @default.
• W2011052290 cites W2116510803 @default.
• W2011052290 cites W2116913457 @default.
• W2011052290 cites W2123618955 @default.
• W2011052290 cites W2128743785 @default.
• W2011052290 cites W2133121894 @default.
• W2011052290 cites W2133922592 @default.
• W2011052290 cites W2134622893 @default.
• W2011052290 cites W2136945880 @default.
• W2011052290 cites W2159307889 @default.
• W2011052290 cites W2161888197 @default.
• W2011052290 cites W2163117814 @default.
• W2011052290 cites W2163765308 @default.
• W2011052290 cites W2163995382 @default.
• W2011052290 cites W2170857957 @default.
• W2011052290 doi "https://doi.org/10.1093/cid/cir066" @default.
• W2011052290 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21427394" @default.
• W2011052290 hasPublicationYear "2011" @default.
• W2011052290 type Work @default.
• W2011052290 sameAs 2011052290 @default.
• W2011052290 citedByCount "59" @default.
• W2011052290 countsByYear W20110522902012 @default.
• W2011052290 countsByYear W20110522902013 @default.
• W2011052290 countsByYear W20110522902014 @default.
• W2011052290 countsByYear W20110522902015 @default.
• W2011052290 countsByYear W20110522902016 @default.
• W2011052290 countsByYear W20110522902017 @default.
• W2011052290 countsByYear W20110522902018 @default.
• W2011052290 countsByYear W20110522902019 @default.
• W2011052290 countsByYear W20110522902020 @default.
• W2011052290 countsByYear W20110522902021 @default.
• W2011052290 countsByYear W20110522902022 @default.
• W2011052290 crossrefType "journal-article" @default.
• W2011052290 hasAuthorship W2011052290A5000301162 @default.
• W2011052290 hasAuthorship W2011052290A5004444553 @default.
• W2011052290 hasAuthorship W2011052290A5019096760 @default.
• W2011052290 hasAuthorship W2011052290A5024601202 @default.
• W2011052290 hasAuthorship W2011052290A5033289218 @default.
• W2011052290 hasAuthorship W2011052290A5047802528 @default.
• W2011052290 hasAuthorship W2011052290A5060978851 @default.
• W2011052290 hasAuthorship W2011052290A5063465178 @default.
• W2011052290 hasAuthorship W2011052290A5067883811 @default.
• W2011052290 hasAuthorship W2011052290A5084119337 @default.
• W2011052290 hasAuthorship W2011052290A5090736522 @default.
• W2011052290 hasBestOaLocation W20110522901 @default.
• W2011052290 hasConcept C126322002 @default.
• W2011052290 hasConcept C141071460 @default.
• W2011052290 hasConcept C168563851 @default.
• W2011052290 hasConcept C203014093 @default.
• W2011052290 hasConcept C2776120307 @default.
• W2011052290 hasConcept C2778048844 @default.
• W2011052290 hasConcept C2778118209 @default.
• W2011052290 hasConcept C2778371730 @default.
• W2011052290 hasConcept C2778629330 @default.
• W2011052290 hasConcept C2780780316 @default.
• W2011052290 hasConcept C44249647 @default.
• W2011052290 hasConcept C71924100 @default.
• W2011052290 hasConcept C82789193 @default.
• W2011052290 hasConcept C90924648 @default.
• W2011052290 hasConceptScore W2011052290C126322002 @default.
• W2011052290 hasConceptScore W2011052290C141071460 @default.
• W2011052290 hasConceptScore W2011052290C168563851 @default.
• W2011052290 hasConceptScore W2011052290C203014093 @default.
• W2011052290 hasConceptScore W2011052290C2776120307 @default.
• W2011052290 hasConceptScore W2011052290C2778048844 @default.
• W2011052290 hasConceptScore W2011052290C2778118209 @default.

• next